| Subject |
The Phase 3 MRCT data and the Taiwan real-world cases of the DFU new drug, Fespixon have been accepted for an oral presentation at the 59th EASD |
- Date of institutional investor conference:2023/10/03
- Time of institutional investor conference:16:45 (TPE time)
- Location of institutional investor conference:Hamburg, Germany
- Outline of institutional investor conference:
(1)The Phase 3 MRCT data and the Taiwan real-world cases of the DFU new drug, Fespixon have been accepted for an oral presentation at the 59th EASD Annual Meeting.
(2)The European Association for the Study of Diabetes (EASD) has been established since 1965. The EASD Annual Meeting has been one of the largest and most reputable scientific congress on diabetes in Europe.The congress covers diabetes-related researches and focuses in the important progress of fundamental science, prevention, diagnosis and treatments in diabetes.
- Any other matters that need to be specified:The presentation slides will be made publicly by being uploaded to Market Observation Post System according to the regulation.
|
